202 related articles for article (PubMed ID: 28522938)
1. Mucin-1-Antibody-Conjugated Mesoporous Silica Nanoparticles for Selective Breast Cancer Detection in a Mucin-1 Transgenic Murine Mouse Model.
Dréau D; Moore LJ; Alvarez-Berrios MP; Tarannum M; Mukherjee P; Vivero-Escoto JL
J Biomed Nanotechnol; 2016 Dec; 12(12):2172-2184. PubMed ID: 28522938
[TBL] [Abstract][Full Text] [Related]
2. A Folate-Conjugated Dual-Modal Fluorescent Magnetic Resonance Imaging Contrast Agent that Targets Activated Macrophages In Vitro and In Vivo.
Yao Y; Li B; Yin C; Cong F; Ma GS; Liu NF; Fan QL; Teng GJ
J Biomed Nanotechnol; 2016 Dec; 12(12):2161-71. PubMed ID: 29372808
[TBL] [Abstract][Full Text] [Related]
3. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer.
Mukherjee P; Madsen CS; Ginardi AR; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
J Immunother; 2003; 26(1):47-62. PubMed ID: 12514429
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a novel monoclonal antibody against tumor-associated MUC1 for diagnosis and prognosis of breast cancer.
Stergiou N; Nagel J; Pektor S; Heimes AS; Jäkel J; Brenner W; Schmidt M; Miederer M; Kunz H; Roesch F; Schmitt E
Int J Med Sci; 2019; 16(9):1188-1198. PubMed ID: 31588183
[TBL] [Abstract][Full Text] [Related]
5. Dual-target recognition sandwich assay based on core-shell magnetic mesoporous silica nanoparticles for sensitive detection of breast cancer cells.
Wang W; Liu S; Li C; Wang Y; Yan C
Talanta; 2018 May; 182():306-313. PubMed ID: 29501157
[TBL] [Abstract][Full Text] [Related]
6. Dual aptamer-functionalized silica nanoparticles for the highly sensitive detection of breast cancer.
Jo H; Her J; Ban C
Biosens Bioelectron; 2015 Sep; 71():129-136. PubMed ID: 25897882
[TBL] [Abstract][Full Text] [Related]
7. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model.
Rowse GJ; Tempero RM; VanLith ML; Hollingsworth MA; Gendler SJ
Cancer Res; 1998 Jan; 58(2):315-21. PubMed ID: 9443411
[TBL] [Abstract][Full Text] [Related]
8. MUC1 aptamer-conjugated mesoporous silica nanoparticles effectively target breast cancer cells.
Hanafi-Bojd MY; Moosavian Kalat SA; Taghdisi SM; Ansari L; Abnous K; Malaekeh-Nikouei B
Drug Dev Ind Pharm; 2018 Jan; 44(1):13-18. PubMed ID: 28832225
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody conjugated magnetic nanoparticles could target MUC-1-positive cells in vitro but not in vivo.
Shanehsazzadeh S; Gruettner C; Lahooti A; Mahmoudi M; Allen BJ; Ghavami M; Daha FJ; Oghabian MA
Contrast Media Mol Imaging; 2015; 10(3):225-36. PubMed ID: 25327822
[TBL] [Abstract][Full Text] [Related]
10. In vivo tumor vasculature targeted PET/NIRF imaging with TRC105(Fab)-conjugated, dual-labeled mesoporous silica nanoparticles.
Chen F; Nayak TR; Goel S; Valdovinos HF; Hong H; Theuer CP; Barnhart TE; Cai W
Mol Pharm; 2014 Nov; 11(11):4007-14. PubMed ID: 24937108
[TBL] [Abstract][Full Text] [Related]
11. Immunity to murine breast cancer cells modified to express MUC-1, a human breast cancer antigen, in transgenic mice tolerant to human MUC-1.
Carr-Brendel V; Markovic D; Ferrer K; Smith M; Taylor-Papadimitriou J; Cohen EP
Cancer Res; 2000 May; 60(9):2435-43. PubMed ID: 10811121
[TBL] [Abstract][Full Text] [Related]
12. Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles.
Wu ST; Fowler AJ; Garmon CB; Fessler AB; Ogle JD; Grover KR; Allen BC; Williams CD; Zhou R; Yazdanifar M; Ogle CA; Mukherjee P
BMC Cancer; 2018 Apr; 18(1):457. PubMed ID: 29685122
[TBL] [Abstract][Full Text] [Related]
13. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
14. A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells.
Shen Y; Li M; Liu T; Liu J; Xie Y; Zhang J; Xu S; Liu H
Int J Nanomedicine; 2019; 14():4029-4044. PubMed ID: 31213813
[No Abstract] [Full Text] [Related]
15. One-step detection of circulating tumor cells in ovarian cancer using enhanced fluorescent silica nanoparticles.
Kim JH; Chung HH; Jeong MS; Song MR; Kang KW; Kim JS
Int J Nanomedicine; 2013; 8():2247-57. PubMed ID: 23818781
[TBL] [Abstract][Full Text] [Related]
16. MUC1 aptamer-capped mesoporous silica nanoparticles for controlled drug delivery and radio-imaging applications.
Pascual L; Cerqueira-Coutinho C; García-Fernández A; de Luis B; Bernardes ES; Albernaz MS; Missailidis S; Martínez-Máñez R; Santos-Oliveira R; Orzaez M; Sancenón F
Nanomedicine; 2017 Nov; 13(8):2495-2505. PubMed ID: 28842375
[TBL] [Abstract][Full Text] [Related]
17. CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.
Zhou R; Yazdanifar M; Roy LD; Whilding LM; Gavrill A; Maher J; Mukherjee P
Front Immunol; 2019; 10():1149. PubMed ID: 31178870
[TBL] [Abstract][Full Text] [Related]
18. The Tat-conjugated N-terminal region of mucin antigen 1 (MUC1) induces protective immunity against MUC1-expressing tumours.
Yang H; Cho NH; Seong SY
Clin Exp Immunol; 2009 Nov; 158(2):174-85. PubMed ID: 19737144
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells.
Chen D; Xia J; Tanaka Y; Chen H; Koido S; Wernet O; Mukherjee P; Gendler SJ; Kufe D; Gong J
Immunology; 2003 Jun; 109(2):300-7. PubMed ID: 12757626
[TBL] [Abstract][Full Text] [Related]
20. A versatile nanoplatform for synergistic chemo-photothermal therapy and multimodal imaging against breast cancer.
Li T; Geng Y; Zhang H; Wang J; Feng Y; Chen Z; Xie X; Qin X; Li S; Wu C; Liu Y; Yang H
Expert Opin Drug Deliv; 2020 May; 17(5):725-733. PubMed ID: 32098527
[No Abstract] [Full Text] [Related]
[Next] [New Search]
